top of page

NASH News | Updates | Liver disease

May 26, 2022

FDA granted fast track designation for ervogastat/clesacostat for the treatment of NASH

Pizer announced that the U.S. Food and Drug Administration (FDA) granted fast-track designation to Pfizer’s investigational combination therapy, ervogastat/clesacostat, for treating patients with non-alcoholic steatohepatitis (NASH) with liver fibrosis.

The fast track designation was provided based on the Phase 2a clinical study, in which ervogastat/clesacostat reduced the liver fat and showed a favourable safety profile.

Fastrack designation is given to those drugs which address the patients with high unmet needs and are indicated to treat or prevent serious diseases.


Recent Posts

See All


bottom of page